The present invention relates to a vaccine composition comprising as an active ingredient an effective amount of an isolated S. pneumoniae phosphoenolpyruvate protein phosphotransferase (PPP, Accession No. NP_345645), optionally together with one or more pharmaceutically acceptable adjuvant(s).